Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
35
AQST Quote, Financials, Valuation and Earnings
Last price:
$5.98
Seasonality move
:
-1.28%
Day range:
$5.84 - $6.05
52-week range:
$2.12 - $7.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.66x
P/B ratio:
--
Volume:
1.6M
Avg. volume:
2.5M
1-year change:
69.6%
Market cap:
$729.6M
Revenue:
$57.6M
EPS (TTM):
-$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
|
$12.9M | -$0.11 | 12.43% | -32.26% | $10.56 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.4B | $1.99 | 12.86% | 19.35% | $599.60 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 31.31% | 54.16% | $1,093.22 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$247.7M | -$1.99 | 200.72% | -82.86% | $603.47 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
RNAZ
TransCode Therapeutics, Inc.
|
-- | -$0.33 | -- | -98.73% | $10.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
|
$5.98 | $10.56 | $729.6M | -- | $0.00 | 0% | 13.66x |
|
ISRG
Intuitive Surgical, Inc.
|
$577.15 | $599.60 | $204.6B | 76.39x | $0.00 | 0% | 21.83x |
|
LLY
Eli Lilly & Co.
|
$1,076.98 | $1,093.22 | $963.9B | 53.26x | $1.50 | 0.56% | 16.52x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$602.82 | $603.47 | $13.7B | -- | $0.00 | 0% | 18.05x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
RNAZ
TransCode Therapeutics, Inc.
|
$7.43 | $10.00 | $6.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
|
103.29% | 2.367 | 18.95% | 5.42x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.065 | -- | 3.42x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
RNAZ
TransCode Therapeutics, Inc.
|
-- | 9.086 | -- | 0.96x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
|
$8.3M | -$11.5M | -91.28% | -- | -89.63% | -$12.9M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
RNAZ
TransCode Therapeutics, Inc.
|
-$4.8K | -$4.6M | -766.9% | -775.26% | -- | -$4.1M |
Aquestive Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AQST or ISRG?
Intuitive Surgical, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of 28.31%. Aquestive Therapeutics, Inc.'s return on equity of -- beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About AQST or ISRG?
Aquestive Therapeutics, Inc. has a consensus price target of $10.56, signalling upside risk potential of 79.82%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.89%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AQSTAquestive Therapeutics, Inc.7 0 0 ISRGIntuitive Surgical, Inc.14 11 1 -
Is AQST or ISRG More Risky?
Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock AQST or ISRG?
Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AQST or ISRG?
Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 76.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 13.66x versus 21.83x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AQSTAquestive Therapeutics, Inc.13.66x -- $12.8M -$15.4M ISRGIntuitive Surgical, Inc.21.83x 76.39x $2.5B $709.2M
-
Which has Higher Returns AQST or LLY?
Eli Lilly & Co. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of 31.72%. Aquestive Therapeutics, Inc.'s return on equity of -- beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About AQST or LLY?
Aquestive Therapeutics, Inc. has a consensus price target of $10.56, signalling upside risk potential of 79.82%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Aquestive Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings AQSTAquestive Therapeutics, Inc.7 0 0 LLYEli Lilly & Co.18 7 0 -
Is AQST or LLY More Risky?
Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock AQST or LLY?
Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AQST or LLY?
Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 13.66x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AQSTAquestive Therapeutics, Inc.13.66x -- $12.8M -$15.4M LLYEli Lilly & Co.16.52x 53.26x $17.6B $5.6B
-
Which has Higher Returns AQST or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of -39.75%. Aquestive Therapeutics, Inc.'s return on equity of -- beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About AQST or MDGL?
Aquestive Therapeutics, Inc. has a consensus price target of $10.56, signalling upside risk potential of 79.82%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.11%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AQSTAquestive Therapeutics, Inc.7 0 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is AQST or MDGL More Risky?
Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock AQST or MDGL?
Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AQST or MDGL?
Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Aquestive Therapeutics, Inc.'s net income of -$15.4M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 13.66x versus 18.05x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AQSTAquestive Therapeutics, Inc.13.66x -- $12.8M -$15.4M MDGLMadrigal Pharmaceuticals, Inc.18.05x -- $287.3M -$114.2M
-
Which has Higher Returns AQST or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of -255.85%. Aquestive Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About AQST or NBY?
Aquestive Therapeutics, Inc. has a consensus price target of $10.56, signalling upside risk potential of 79.82%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Aquestive Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AQSTAquestive Therapeutics, Inc.7 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is AQST or NBY More Risky?
Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock AQST or NBY?
Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AQST or NBY?
Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 13.66x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AQSTAquestive Therapeutics, Inc.13.66x -- $12.8M -$15.4M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns AQST or RNAZ?
TransCode Therapeutics, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of --. Aquestive Therapeutics, Inc.'s return on equity of -- beat TransCode Therapeutics, Inc.'s return on equity of -775.26%.
Company Gross Margin Earnings Per Share Invested Capital AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M -
What do Analysts Say About AQST or RNAZ?
Aquestive Therapeutics, Inc. has a consensus price target of $10.56, signalling upside risk potential of 79.82%. On the other hand TransCode Therapeutics, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 3668.51%. Given that TransCode Therapeutics, Inc. has higher upside potential than Aquestive Therapeutics, Inc., analysts believe TransCode Therapeutics, Inc. is more attractive than Aquestive Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AQSTAquestive Therapeutics, Inc.7 0 0 RNAZTransCode Therapeutics, Inc.0 0 0 -
Is AQST or RNAZ More Risky?
Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison TransCode Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AQST or RNAZ?
Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransCode Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. TransCode Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AQST or RNAZ?
Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than TransCode Therapeutics, Inc. quarterly revenues of --. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than TransCode Therapeutics, Inc.'s net income of -$4.9M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while TransCode Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 13.66x versus -- for TransCode Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AQSTAquestive Therapeutics, Inc.13.66x -- $12.8M -$15.4M RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
